2021 has not been a great season when it comes to corporate movements in the pharmaceutical industry. In fact, it was not until the end of the year that the most important acquisitions took place. A wave of purchases that took the investment in mergers to 71,300 million euros.
The most important of these operations was closed on December 15. the australian company CSL launched a takeover bid (takeover bid) to acquire all the shares of Vifor Pharma for a total of 10.39 billion euros ($11.7 billion).
A movement that came almost a month after Vifor Pharma announced the purchase of the Spanish Sanifit. Under the agreement, Sanifit shareholders would receive an initial payment of €205 million, as well as additional payments of up to €170 million that would be linked to the achievement of certain clinical, regulatory and market access milestones.
Returning to the most important purchase operations -compiled by the Evaluate Pharma consultancy-, second place is occupied by MSDafter acquiring Aceleron Pharma. The agreement was closed in November of last year for a total amount of 10,135 million euros (11,500 million dollars).
This was the main operation in the third quarter, the period in which the agreement was announced. A movement that was to be expected after the spin-off of Organon, since the US company had capital to ‘go shopping’.
In fact, the president of the pharmaceutical company, Robert M. Davis, said that this spin-off allowed the company to “seek new opportunities for business development.”
The podium completes it the purchase of GW by Jazz Pharmaceuticals, for 6,345 million euros (7,200 million dollars). This operation was announced in February 2021.
But, as we have mentioned before, it was at the end of the year that a boom of acquisitions. In this period is framed, precisely, the movement of Pfizer to buy Arena Pharmaceuticals for €5.9 billion ($6.7 billion).
Somewhat lower was the operation of Novo Nordisk. The drugmaker announced in November an agreement to acquire Dicerna Pharmaceuticals for 2.908 million euros ($3.3 billion).
Evolution of operations
Last year closed with a volume in mergers and acquisitions in the pharmaceutical sector lower than that achieved in 2020. In total, the operations mobilized more than 71,300 million euros (80,900 million dollars).
A figure far from 106,115 million euros (120,400 million dollars) that were achieved in 2020although higher than that of 2017. Thus, 2021 closed without registering a ‘mega-purchase’ (operations of more than 25,000 million), something that has happened in previous years.
Looking ahead to 2022, biotech investors expect a increased activity of mergers and acquisitions after registering a “quiet” 2021.